New depression drug DT-101 enters Mid-Stage trial
NCT ID NCT07610473
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether DT-101 can ease depression symptoms in adults with major depressive disorder who are already on antidepressant medication. About 118 participants will receive either DT-101 or a placebo, and researchers will track changes in depression scores over 56 days. The goal is to see if DT-101 offers additional benefit beyond standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DT-101
What this could lead to
If it works, this could provide a new treatment option for people with major depressive disorder who are already on medication.
What could go wrong
This is an early-phase trial with only 118 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER (MDD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Draig Clinical Site
RECRUITINGDeSoto, Texas, 75115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Draig Clinical Site
RECRUITINGMiami, Texas, 33166, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••